Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient Enquiry under NPP.
RXULTI 0.25 mg film-coated tablet
Brexpiprazole is used to treat mental conditions, including depression and schizophrenia. It is also used to treat agitation that may happen with dementia caused by Alzheimer's disease. Brexpiprazole is an antipsychotic agent. It works in the brain to change how certain chemicals affect patients.
Rxulti is an antipsychotic medicine used to treat schizophrenia in adults. Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (seeing, hearing or feeling things that are not there). Rxulti contains the active substance brexpiprazole.
Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer’s disease. It is an atypical antipsychotic.
In the United States and Canada, brexpiprazole is indicated as an adjunctive therapy to antidepressants for the treatment of major depressive disorder and for the treatment of schizophrenia. In May 2023, the indication for brexpiprazole was expanded in the US to include the treatment of agitation associated with dementia due to Alzheimer’s disease.
In Australia and the European Union, brexpiprazole is indicated for the treatment of schizophrenia.
In 2020, it was approved in Brazil only as an adjunctive to the treatment of major depressive disorder.
Drug (Brand / Generic): RXULTI / brexpiprazole
Current Indications: schizophrenia
Marketed by:: Otsuka Pharmaceutical Netherlands B.V.
Approval Date: 26/07/2018
Dosage forms and strengths of RXULTI 0.25 mg film-coated tablet
RXULTI 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg film-coated tablets
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ RXULTI (brexpiprazole) tablet ”. Confirmation of the order for RXULTI (brexpiprazole) tablet will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – RXULTI
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha